Holen Sie sich die Stockscreener-App
3.21
4.46%
-0.15
Handel nachbörslich:
3.22
0.01
+0.31%
Schlusskurs vom Vortag:
$3.36
Offen:
$3.28
24-Stunden-Volumen:
40,554
Relative Volume:
0.33
Marktkapitalisierung:
$37.58M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.25M
KGV:
-1.8034
EPS:
-1.78
Netto-Cashflow:
$-17.87M
1W Leistung:
-9.32%
1M Leistung:
-19.14%
6M Leistung:
-3.31%
1J Leistung:
+1.58%
1-Tages-Spanne:
$3.1579
$3.3865
1-Wochen-Bereich:
$3.1579
$3.70
52-Wochen-Spanne:
$2.55
$6.118
Lantern Pharma Inc Stock (LTRN) Company Profile
Firmenname
Lantern Pharma Inc
Sektor
Branche
Telefon
972-277-1136
Adresse
1920 MCKINNEY AVENUE, DALLAS, TX
Vergleichen Sie LTRN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
3.21 | 37.58M | 0 | -19.25M | -17.87M | -1.78 |
|
ARGX
Argen X Se Adr
|
918.53 | 57.24B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.52 | 110.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
INSM
Insmed Inc
|
201.62 | 42.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
ONC
Beone Medicines Ltd Adr
|
363.92 | 41.68B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
725.34 | 74.02B | 14.25B | 4.58B | 3.88B | 41.77 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-10-07 | Eingeleitet | H.C. Wainwright | Buy |
Lantern Pharma Inc Aktie (LTRN) Neueste Nachrichten
Is Lantern Pharma Inc. stock oversold or undervaluedTrade Signal Summary & Risk Managed Investment Strategies - newser.com
How Lantern Pharma Inc. stock reacts to global recession fearsEarnings Overview Summary & Reliable Price Breakout Alerts - newser.com
Is Lantern Pharma Inc. stock vulnerable to regulatory risksQuarterly Portfolio Summary & Free Low Drawdown Momentum Trade Ideas - newser.com
Lantern Pharma Engages New to The Street for National Media Coverage Featuring Television, Press, Earned Media and Non-Deal Investor Focused Roadshows - Gadsden Times
How Lantern Pharma Inc. stock performs in weak economyWeekly Volume Report & Fast Entry and Exit Trade Plans - newser.com
Using economic indicators to assess Lantern Pharma Inc. potentialQuarterly Trade Report & Daily Stock Trend Reports - newser.com
Can Lantern Pharma Inc. stock deliver consistent earnings growthMarket Sentiment Report & AI Forecast for Swing Trade Picks - newser.com
Lantern Pharma (NASDAQ:LTRN) Will Have To Spend Its Cash Wisely - Yahoo Finance
Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2025 Earnings Call Transcript - Insider Monkey
Lantern Pharma’s Earnings Call: Progress and Funding Needs - TipRanks
Lantern Pharma’s Q3 2025: Clinical and AI Progress - TipRanks
Lantern Pharma (NASDAQ: LTRN) Reports Q3 2025 Results and Highlights AI-Driven Clinical Progress - Digital Journal
Transcript : Lantern Pharma Inc., Q3 2025 Earnings Call, Nov 13, 2025 - MarketScreener
Will Lantern Pharma Inc. stock maintain dividend yieldBreakout Watch & Free Risk Controlled Daily Trade Plans - newser.com
LTRN: Pivotal quarter with clinical milestones, AI platform advances, and cash runway into Q3 2026 - TradingView
Earnings call transcript: Lantern Pharma Q3 2025 sees stock rise after earnings - Investing.com India
Lantern Pharma : Q3 2025 Earnings Call - MarketScreener
Lantern Pharma Achieves Key Milestones in Q3 2025 - TipRanks
Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates - Business Wire
Full technical analysis of Lantern Pharma Inc. stock2025 Short Interest & Community Consensus Picks - newser.com
Lantern Pharma Earnings Preview - Benzinga
Lake Street Schedules Virtual Meeting for November 20 with LTRN Focus - GuruFocus
Lantern Pharma Q3 2025 Earnings Call Transcript - MarketBeat
How Lantern Pharma Inc. stock reacts to oil pricesMarket Risk Report & Daily Stock Momentum Reports - newser.com
Is Lantern Pharma Inc. stock a buy before product launchesJuly 2025 Catalysts & Safe Investment Capital Preservation Plans - newser.com
Lantern Pharma (NASDAQ: LTRN) CEO Discusses AI-Driven Cancer Drug Development in FintechTV Interview at NYSE - Digital Journal
Lantern Pharma Inc. stock trendline breakdownEarnings Summary Report & Community Trade Idea Sharing - newser.com
Is Lantern Pharma Inc. stock attractive for income investorsWatch List & Stepwise Trade Signal Guides - newser.com
Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Lancaster Eagle-Gazette
Lantern Pharma (LTRN) Partners with New to The Street for Extens - GuruFocus
When is the best time to exit Lantern Pharma Inc.Trade Ideas & AI Optimized Trading Strategy Guides - newser.com
Lantern Pharma (NASDAQ: LTRN) Sets Nov. 13 Webcast to Review Q3 2025 Results and AI Platform Developments - The Globe and Mail
Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET - BioSpace
Finanzdaten der Lantern Pharma Inc-Aktie (LTRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.08%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):